Rights issue
ExonHit Therapeutics, which is quoted on the Alternext market in Paris, has launched a €15.6 million rights issue to finance the acquisition of a diagnostics company and for ongoing operations.
“The new funding will allow us to take advantage of external opportunities for growth, particularly in the US”, said Loïc Maurel, President of Exonhit. “We also intend to grow our sales force to speed development of the market for our AclarusDx diagnostic blood test for Alzheimer’s disease.”
The company is issuing 4.2 million new shares at €3.75 each, and may issue a further 5.5 million shares in an extension to the offer.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
